PTO/SB/08b (07-09)

Approved for use through 07/31/2012, OMB 0851-0031

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449/PTO			ct of 1995, no persons ar	re required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known		
				Application Number	10/575,671	
INFORMATION DISCLOSURE				Filing Date	July 25, 2008	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Bradley T. Messmer	
(Use as many sheets as necessary)				Art Unit	1642	
				Examiner Name	Sean E. Aeder	
Sheet	1	of	2	Attorney Docket Number	50425/245	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	e Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issu number(s), publisher, city and/or country where published.			
	1	A copy of the International Search Report for PCT Application No. PCT/US2004/033176. 6/16/05			
	2	A copy of the Written Opinion of the International Searching Authority for PCT Application No. PCT/US2004/033176. 6/16/05			
	3	A copy of the International Preliminary Report on Patentability for PCT Application No. PCT/US2004/033176. 6/16/05			
	4	A copy of the Office Action for European Application No. 04 794 503.5, dated February 2, 2010.			
	5	A copy of the Office Action for European Application No. 04 794 503.5, dated April 9, 2008.			
	6	VALETTO et al. "Chronic Lymphoid Leukemia." Bio. and Clin. Invest. III, Abstract #1784, p. 431a. 1998			
	7	FAIS et al. "Chronic Lymphocytic Leukemia B Cells Express Restricted Sets of Mutated and Unmutated Antigen Receptors." J. Clin. Invest. (1998), vol. 102, pp. 1515-25.			
		DAMLE et al. "Ig V Gene Mutation Status and CD38 Expression as Novel Prognostic Indicators in Chronic Lymphocytic Leukemia." Blood, Sept. 15, vol. 94, pp. 1840-47.			
	9 CHIORAZZI et al. "Immunoglobulin Variable Region Gene Characteristics and Surfac Membrane Phenotype Define B-CLL Subgroups with Distinct Clinical Courses."				
		Chronic Lymphoid Leukemia, Marcel Dekker, New York, NY, US (2001) pp. 81-109.			

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

considered, include copy of this form in next communication to applicate.

Applicant's roung clutter designation manufacting depth and a page a Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

if you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/085 (07-09)

Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449/PTO				re required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known		
Substitute for form 1444/PTO				Application Number	10/575,671	
INFORMATION DISCLOSURE				Filing Date	July 25, 2008	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Bradley T. Messmer	
(Use as many sheets as necessary)				Art Unit	1642	
				Examiner Name	Sean E. Aeder	
Sheet	1	of	2	Attorney Docket Number	50425/245	

_	0:11	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	10	GHIOTTO et al. "Remarkably Similar Antigen Receptors Among a Subset of Patients with Chronic Lymphocytic Leukemia." J. of Clin. Invest. Vol. 113:7, pp. 1008-1011.	
	11	CARTER "Improving the Efficacy of Antibody-Based Cancer Therapies." Nature Reviews (2001) vol. 1, pp. 119-129.	
	12	CHIORAZZI et al. "B Cell Chronic Lymphocytic Leukemia: Lessons Learned from Studies of the B Cell Antigen Receptor." Annu. Rev. Immunol. 2005, 21:841-894.	
***************************************			

Examiner Signature	/Sean Aeder/ (01/14/2011)	Date Considered	

<sup>\*</sup>EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Tapplicar's unique discount on segmentor humber (ejoridan), «Applicant is to passe a creat X main result in legal and mainly and intallessions) as succession of the procession of the processio

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.